Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.73 |
| ▸ | EGFR | P00533 | 11/20 | 0.73 |
| ▸ | FLT4 | P35916 | 9/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.73 |
| ▸ | FLT1 | P17948 | 9/20 | 0.73 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 6/20 | 0.52 |
| ▸ | KIF5B | P33176 | 5/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200083 | 0.91 | EGFR (0.73) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL2203010 | 0.89 | FLT1 (0.73) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL7477739 | 0.88 | FLT1 (0.75) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL2139502 | 0.84 | KDR (1.00) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL5649183 | 0.84 | EGFR (0.62) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL2200924 | 0.82 | KDR (0.74) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL1008026 | 0.82 | KDR (0.72) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL7209985 | 0.82 | KDR (0.70) | KDREGFRFLT4FGFR1FLT1 | |
| Water SCHEMBL27735443 | 0.81 | KDR (0.71) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL6454560 | 0.81 | KDR (0.71) | KDREGFRFLT4FGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3522727-B2 | — | — | 2004-04-26 | — | — | JP | claimed |
| JP-2003513089-A | — | — | 2003-04-08 | — | — | JP | claimed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | claimed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010045344-A1 | COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045345-A2 | TREATMENT METHOD | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009111691-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |